BIOMAT Database Logo BIOMAT Database Logo

Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. 1992

V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Department of Virus and Cell Biology, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486-0004.

Several novel, structurally distinct classes of specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) nonnucleoside inhibitors have been described recently. These include the pyridinone derivatives L-697,639, L-697,661, and L-696,229 as well as BI-RG-587 and the tetrahydroimidazo[4,5,1-j,k]-benzodiazepin-2(1H)-one and -thione compounds. Previous studies have implicated involvement of the RT amino acid residues at positions 103, 181, and 188 in the activity of the compounds. Accordingly, HIV-1 RT mutants containing a series of amino acid substitutions at these positions were constructed. The relative resistance of purified mutant enzymes to each of the inhibitors was assessed. This analysis established the functional equivalence of the three inhibitor classes and provided evidence for the interaction of the 103 site with the 181/188 region. Amino acid substitutions at these positions were also found to influence RT sensitivity to inhibition by phosphonoformate, thereby suggesting a close association between this pyrophosphate analog's binding site in RT and the binding site of the nonnucleoside inhibitors. In addition, aromatic stacking of the amino acid side groups at residues 181 and 188 was suggested to be required for inhibitor activity.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds

Related Publications

V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
November 2013, Antimicrobial agents and chemotherapy,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Development of nonnucleoside HIV reverse transcriptase inhibitors.
January 1996, Methods in enzymology,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
November 2006, PLoS pathogens,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
October 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.
July 2014, Viruses,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Nonnucleoside reverse transcriptase inhibitors.
October 1997, AIDS clinical care,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Novel diarylpyrimidine subtypes as HIV-1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile.
March 2024, Journal of medical virology,
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
February 1995, Science (New York, N.Y.),
V V Sardana, and E A Emini, and L Gotlib, and D J Graham, and D W Lineberger, and W J Long, and A J Schlabach, and J A Wolfgang, and J H Condra
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.
February 2015, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!